| # | Drug | Count |
|---|---|---|
| 0 | CYTARABINE | 70 |
| 1 | CYCLOPHOSPHAMIDE | 50 |
| 2 | CYCLOPHOSPHAMIDE FOR INJECTION | 50 |
| 3 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 50 |
| 4 | ETOPOSIDE | 48 |
| 5 | METHOTREXATE SODIUM | 43 |
| 6 | AZACITIDINE | 41 |
| 7 | METHOTREXATE | 39 |
| 8 | FLUDARABINE PHOSPHATE | 36 |
| 9 | DOXORUBICIN | 34 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | GLASDEGIB | 3 | 0.0063 |
| 1 | DEXTRAN, HYPROMELLOSE | 1 | 0.0043 |
| 2 | SILTUXIMAB | 2 | 0.0031 |
| 3 | MITOXANTRONE HYDROCHLORIDE | 18 | 0.0029 |
| 4 | BLEOMYCIN SULFATE | 26 | 0.0025 |
| 5 | AMINOCAPROIC ACID | 2 | 0.0025 |
| 6 | CHLOROTHIAZIDE SODIUM | 2 | 0.0022 |
| 7 | GILTERITINIB | 8 | 0.0020 |
| 8 | TAGRAXOFUSP | 1 | 0.0019 |
| 9 | CLOFARABINE | 4 | 0.0017 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nucleoside Metabolic Inhibitor [EPC] | 102 |
| 1 | Alkylating Drug [EPC] | 68 |
| 2 | Corticosteroid [EPC] | 64 |
| 3 | Platinum-based Drug [EPC] | 48 |
| 4 | Topoisomerase Inhibitor [EPC] | 48 |
| 5 | Folate Analog Metabolic Inhibitor [EPC] | 39 |
| 6 | Kinase Inhibitor [EPC] | 31 |
| 7 | BCL-2 Inhibitor [EPC] | 28 |
| 8 | CD20-directed Cytolytic Antibody [EPC] | 23 |
| 9 | Microtubule Inhibitor [EPC] | 18 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-6 Antagonist [EPC] | 2 | 0.0031 |
| 1 | CD123 Interaction [EPC] | 1 | 0.0019 |
| 2 | CD33-directed Immunoconjugate [EPC] | 5 | 0.0014 |
| 3 | Anthracycline Topoisomerase Inhibitor [EPC] | 3 | 0.0012 |
| 4 | CD22-directed Immunoconjugate [EPC] | 2 | 0.0007 |
| 5 | Topoisomerase Inhibitor [EPC] | 48 | 0.0006 |
| 6 | BCL-2 Inhibitor [EPC] | 28 | 0.0004 |
| 7 | Erythroid Maturation Agent [EPC] | 1 | 0.0004 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 102 | 0.0004 |
| 9 | Plasma Volume Expander [EPC] | 1 | 0.0003 |